Triumvira Appoints Oncology Industry Veteran Deyaa Adib, M.D., as Chief Medical Officer

Oct. 28, 2021 12:00 UTC



AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)-- Triumvira Immunologics, Inc. (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it has appointed Deyaa Adib, M.D., to serve as the company’s Chief Medical Officer, effective immediately. Dr. Adib will report to President and CEO Dr. Paul Lammers and will succeed Dr. Sabine Chlosta.

This press release features multimedia. View the full release here:

Deyaa Adib, M.D. (Photo: Business Wire)

Deyaa Adib, M.D. (Photo: Business Wire)

As a seasoned industry leader, Dr. Adib has over 24 years of medical oncology experience in the biotechnology and pharmaceutical industries, including seven successful registrations across solid tumor and hematologic malignancy indications. He previously served as acting chief medical officer at Rain Therapeutics, where he built the oncology portfolio leading to a successful IPO, and vice president of late-stage development at Blueprint Medicines advancing the development of avapritinib approved for gastrointestinal stromal tumor and advanced systemic mastocytosis. Dr. Adib also served as global therapeutics head for solid tumors at Baxalta, advancing the development of imalumab in colorectal cancer, non-small cell lung cancer (NSCLC) and ovarian cancer, and licensing nanoliposomal irinotecan that was subsequently approved for pancreatic cancer. In this role, he also led the efforts to secure licensing and development of a CD-19 target with Precision Biosciences in B cell malignancies and PD1, LAG3, TIM3 solid tumor targets with Symphogen, a Servier company. He also served as head of hematologic malignancies at ARIAD Pharmaceuticals (now part of Takeda) leading the global clinical program for ponatinib dose finding and line extension in chronic myeloid leukemia.

“Deyaa’s successful track record of shepherding the clinical development of multiple oncology treatments will be a tremendous asset for Triumvira as we advance clinical studies for our first-in-class pipeline of TAC-T cell therapies,” said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira. “I’m excited to welcome Deyaa to the Triumvira leadership team, and we are grateful to Sabine for her contributions to our development program and wish her success in her future endeavors.”

Dr. Adib has also held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma where he advanced the development of Taxotere in prostate cancer, breast cancer and gastric cancer, oxaliplatin in colorectal cancer, enzalutamide in prostate cancer, quizartinib in acute myeloid leukemia and erlotinib in NSCLC. He held multiple seats as a scientific advisory board member at several biotech companies, including Imbrium Therapeutics, a Purdue Pharma subsidiary. He also provided strategic consulting support to multiple cell therapy startups including KSQ for eTIL™ and Bellicum Pharmaceuticals for GoCAR™.

“I am honored to join Triumvira as Chief Medical Officer and look forward to working with the highly skilled scientific and technical teams to bring Triumvira’s robust pipeline of TAC-T cell therapeutics from the bench to the bedside and registration for patients with solid tumors who need new treatment options to satisfy areas of significant unmet medical need,” said Dr. Adib.

Dr. Adib obtained an M.D. from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate training at the Anglo-American Hospital Association in Cairo, Egypt and additionally at Tufts University School of Medicine in clinical pharmacology, drug development and regulation.

About Triumvira Immunologics

Triumvira Immunologics, Inc. (“Triumvira”) is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.

For more information, please visit or send email inquiries to


Investor Relations:
Stephanie Carrington
ICR Westwicke

Media Relations:
Cammy Duong
ICR Westwicke


Source: Triumvira Immunologics, Inc.

Smart Multimedia Gallery

Deyaa Adib, M.D. (Photo: Business Wire)

View this news release and multimedia online at:

Back to news